相关实验视频

Updated: May 13, 2026

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
08:25

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

15.9K

对临床使用的快速蒙特卡洛剂量引擎进行比较研究,用于质子疗法

Sherif M Gadoue1, Narayan Sahoo1

  • 1Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Journal of applied clinical medical physics
|September 24, 2025
PubMed
概括

质子治疗的快速蒙特卡洛 (MC) 代码在患者剂量计算中显示出高准确性. 单个和双个高斯模型都实现了极好的马通率,验证了它们的临床用途.

关键词:
这就是为什么CPU是CPU.我们的GPU是GPU的GPU蒙特卡罗的蒙特卡罗是一个非常好的城市.质子疗法是一种质子疗法.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K

相关概念视频

Multiple Comparison Tests01:13

Multiple Comparison Tests

Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...